Clinical study of paclitaxel plus cisplatin in the treatment of recurrent cervical cancer

Abstract

Cervical cancer is the most common cause of cancer in women worldwide and the second leading cause of cancer death in the developing countries [1, 2] . The major reason for the treatment failure of cervical cancer is local recurrence and distant metastasis. About 31% of patients developed tumor recurrence after treatment, and 75% of these recurred within 2 years, while up to 70% of patients recurred within the radiation treatment field [3] . Most patients who relapse locally after primary radiotherapy are not candidates for further radiotherapy, selected patients with respectable pelvic central recurrences could considered for pelvic exenteration surgery. But, we have difficulty in treating those patients whose disease involving pelvic side wall, para-aortic node and so on. Now we usually select the cisplatin-based chemotherapy regimens to patients with recurrent cervical cancer, the most effective regimens is still in exploring [4] . Many clinical trails indicated that paclitaxel is an active drug to advanced ovarian cancer, breast cancer and non-small cell lung cancer. It was reported that this drug was effect to recurrent or metastatic cervical cancer. We used the combination regimen of paclitaxel and cisplatin in treating 23 recurrent cervical cancer patients, and achieved good clinical results. Materials and methods CharacteristicsBetween October 2002 and September 2005, 23 patients with recurrent cervical cancer were included in the study. Patient characteristics were listed in Table 1. All patients were histologically confirmed before the initial treatment. While 9 patients were confirmed by pathology again when they were relapsed, 17.4% (4/23) of the patients with lung metastasis were confirmed by radiograph or computed tomography. 43.5% (10/23) of the patients recurred only in the cavitas pelvis, while the vagina and cervix uteri was normal, which had been identified by computed tomography or magnetic resonance imaging. The age of all patients ranged from 35 to 70 (median, 58 years). Eligibility criteria included the following: all patients were required to be performance status of 70 or more on Karnofsky scale, normal white blood cell and platelet counts, and adequate liver and renal function. They all had received the initial treatment. Besides, we can assessed the effect in the near future according to some measurable parameters. MethodsThe chemotherapy regimen was comprised of paclitaxel 135-150 mg/ m 2 infusion for 3 h on day 1, cisplatin 25 mg/ m 2 infusion day 1-3, repeated every 3 weeks. All patients received at least two cycles of the treatment. They took a premedication regimen that includes oral dexamethasone 10 mg administered approximately 12 and 6 Abstract Objective: To observe the efficacy and toxicities of paclitaxel plus cisplatin in the treatment of recurrent cervical cancer. Methods: Twenty-three patients with a diagnosis of recurrent cervical cancer were eligible. Three-weekly chemotherapy regimen consisted of paclitaxel 135-150 mg/m 2 infusion for 3 h on day 1, cisplatin 25 mg/m 2...

Novel composite drug delivery system as a novel radio sensitizer for the local treatment of cervical carcinoma

“…The majority of cervical cancer patients are treated with concurrent chemoradiation therapy, which improves both overall survival and disease-free survival (Denny, 2012). Cisplatin (DDP)-based chemotherapy is widely used and the combination of paclitaxel (PTX) and DDP is known to be effective in treatment of advanced and recurrent cervical cancer with response rates of 40-50% (Song et al, 2007;Mccormack et al, 2013;Mousavia et al, 2013). In addition, the use of PTX and DDP in combination with radiotherapy is a safe and effective treatment method for the treatment of locally advanced cervical cancer (Wang et al, 2015).…”